Methods and compounds for restoring mutant p53 function

Inventors

Vu, Binh • Dominique, Romyr • Li, Hongju

Assignees

PMV Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11339141-B2

Patent

Publication Date

2022-05-24

Expiration Date


Abstract

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Core Innovation

The invention relates to a method comprising determining that a tumor cell in a subject expresses a p53 mutant protein having a Y220C mutation, and administering to the subject a therapeutically-effective amount of a compound based on the determining. The method is tied to tumor cells expressing the p53 mutant protein with the Y220C mutation and uses that determination as the basis for treatment selection in cancer contexts.

The compound is defined by a chemical formula with multiple variable substituents and linker options, including Q, Q1, R1, R2, R3, R4, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, and R24, and includes pharmaceutically-acceptable salts thereof. The formula permits broad options including C(O), C(S), C(R14), C(NR14), alkylene, alkenylene, alkynylene, and related carbonyl-, thio-, amino-, cyano-, azido-, sulfoxide-, sulfone-, sulfonamide-, carboxyl-, ester-, alkyl-, aryl-, heteroaryl-, and heterocyclyl-containing groups.

In the disclosed embodiments, specific compounds are exemplified by indole-based, p53-mutant-targeting small molecules with a 2,2,2-trifluoroethyl group, a prop-1-yn-1-yl or prop-2-yn-1-yl linker, and substituted anilino, pyridinyl sulfonamide, amide, urea, or piperidine/piperazine-like side chains. The disclosure also identifies functional and biological outcomes associated with the compounds, including restoring or increasing p53 DNA binding activity, inducing apoptosis, and cell cycle arrest.

Claims Coverage

The independent claim is directed to a method that combines determining Y220C expression in tumor cells and administering a therapeutically-effective amount of a compound having a defined chemical formula. Across the provided claim summaries, the coverage includes the core mutation-based selection step, the formula-defined compound administration, and dependent refinements relating to mutant selectivity, biological activity, administration route, and dosage.

Determining tumor cell expression of p53 Y220C mutant protein

Determining that a tumor cell in a subject expresses a p53 mutant protein, wherein the p53 mutant protein has a Y220C mutation.

Administering a therapeutically-effective amount of a formula-defined compound

Administering to the subject a therapeutically-effective amount of a compound based on the determining that the tumor cell in the subject expresses the p53 mutant protein, wherein the compound has the formula and includes pharmaceutically-acceptable salts thereof.

Broad variable substituent chemical formula

The compound has a formula with variable groups such as Q, Q1, R1, R2, R3, R4, and additional R-group positions, independently selected from specified structural classes and substitution options.

Preferential binding to mutant p53 over wild type p53

Using a compound that preferentially binds the p53 mutant protein in tumor cells rather than binding the wild type p53 protein.

Increasing p53 mutant DNA binding activity

Using a compound that increases a DNA binding activity of a p53 mutant protein in a tumor cell.

Inducing apoptosis in the tumor cell

Using a compound that binds to a p53 mutant protein in a tumor cell and induces apoptosis in the tumor cell.

Oral administration

Administering the compound orally.

Dose range in mg/kg

Administering the compound at a dosage ranging from about 250 mg/kg to about 2000 mg/kg.

Overall, the claim coverage centers on selecting subjects by determining p53 Y220C expression in tumor cells and administering a therapeutically-effective amount of a structurally defined compound. The dependent claim summaries further emphasize preferential mutant p53 binding, increased DNA binding activity, apoptosis, cell cycle arrest, oral administration, and an explicit dosing range.

Stated Advantages

Restored or increased p53 DNA binding activity.

Preferential binding to the p53 mutant protein rather than binding the wild type p53 protein.

Induction of apoptosis in the tumor cell.

Cell cycle arrest.

Reducing cancer progression.

Restoring wild-type function to mutant p53, including restoring DNA-binding and downstream tumor-suppressive activity.

Documented Applications

Treating a subject having tumor cells that express a p53 mutant protein with a Y220C mutation by administering a therapeutically-effective amount of a compound based on the determining.

Treating cancer in a subject whose tumor cells express a p53 mutant protein having a Y220C mutation.

Providing pharmaceutical compositions for the described therapy.

Administration routes including oral administration, intravenous administration, subcutaneous administration, and topical administration.

Cancer contexts including ovarian cancer, breast cancer, and lung cancer.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.